Patents by Inventor Hongjuan Qiu

Hongjuan Qiu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Compound inhibiting activities of BTK and/or JAK3 kinases
    Patent number: 10273242
    Abstract: The present invention relates to a compound inhibiting the activities of Bruton's tyrosine kinase (BTK) and/or Janus kinase 3 (JAK3), a pharmaceutical composition of the compound, pharmaceutical applications of same, a method for using the compound in inhibiting the activities of BTK and/or JAK3, and a method for using the compound in treatment and/or prevention of BTK- and/or JAK3-mediated diseases or disorders in mammals (especially human). The compound is as represented by structural formula (I).
    Type: Grant
    Filed: October 31, 2017
    Date of Patent: April 30, 2019
    Assignee: BEIJING HANMI PHARMACEUTICAL CO., LTD.
    Inventors: Jinming Liu, Mi Young Cha, Gong Li, Zhanmei Li, Hongjuan Qiu, Maengsup Kim
  • COMPOUND INHIBITING ACTIVITIES OF BTK AND/OR JAK3 KINASES
    Publication number: 20180051036
    Abstract: The present invention relates to a compound inhibiting the activities of Bruton's tyrosine kinase (BTK) and/or Janus kinase 3 (JAK3), a pharmaceutical composition of the compound, pharmaceutical applications of same, a method for using the compound in inhibiting the activities of BTK and/or JAK3, and a method for using the compound in treatment and/or prevention of BTK- and/or JAK3-mediated diseases or disorders in mammals (especially human). The compound is as represented by structural formula (I).
    Type: Application
    Filed: October 31, 2017
    Publication date: February 22, 2018
    Applicant: BEIJING HANMI PHARMACEUTICAL CO., LTD.
    Inventors: Jinming LIU, Mi Young CHA, Gong LI, Zhanmei LI, Hongjuan QIU, Maengsup KIM
  • Compound inhibiting activities of BTK and/or JAK3 kinases
    Patent number: 9840517
    Abstract: The present invention relates to a compound inhibiting the activities of Bruton's tyrosine kinase (BTK) and/or Janus kinase 3 (JAK3), a pharmaceutical composition of the compound, pharmaceutical applications of same, a method for using the compound in inhibiting the activities of BTK and/or JAK3, and a method for using the compound in treatment and/or prevention of BTK- and/or JAK3-mediated diseases or disorders in mammals (especially human). The compound is as represented by structural formula (I).
    Type: Grant
    Filed: September 18, 2014
    Date of Patent: December 12, 2017
    Assignee: BEIJING HANMI PHARMACEUTICAL CO., LTD.
    Inventors: Jinming Liu, Mi Young Cha, Gong Li, Zhanmei Li, Hongjuan Qiu, Maengsup Kim
  • COMPOUND INHIBITING ACTIVITIES OF BTK AND/OR JAK3 KINASES
    Publication number: 20160229865
    Abstract: The present invention relates to a compound inhibiting the activities of Bruton's tyrosine kinase (BTK) and/or Janus kinase 3 (JAK3), a pharmaceutical composition of the compound, pharmaceutical applications of same, a method for using the compound in inhibiting the activities of BTK and/or JAK3, and a method for using the compound in treatment and/or prevention of BTK- and/or JAK3-mediated diseases or disorders in mammals (especially human). The compound is as represented by structural formula (I).
    Type: Application
    Filed: September 18, 2014
    Publication date: August 11, 2016
    Applicant: BEIJING HANMI PHARMACEUTICAL CO., LTD.
    Inventors: Jinming Liu, Mi Young Cha, Gong Li, Zhanmei Li, Hongjuan Qiu, Maengsup Kim